San Jose, California (PRWEB) May 03, 2012
Follow us on LinkedIn – Growth factors (blood and tissue) offer immense potential for applications in diverse areas and are presently finding a firm foothold in the bio-pharmaceutical market. Wound healing represents a key application area for growth factors. Growth factors are presently used as potential therapeutic agents to deal with critical conditions, such as Ranulocytopenia, Leukemia, Aplastic anaemia, Bone marrow transplantation, and Myelodysplastic syndrome. Blood growth factors are gaining immense popularity, owing to several new therapeutic applications, such as colony stimulating factors finding a role in neutropenia prevention and treatment. Brain Derived Neurotrophic Factor (BDNF) is emerging as an efficient alternative to VEGF and FGFs administered to ischemic patients for neo-angiogenesis and neo-vascularization. Also vital for cancer therapies and regenerative medicine, BDNFs are emerging as the preferred therapeutic proteins for organ specific angiogenesis. In the coming years, the increase in the incidence of age-related diseases is expected to be a significant driver for the growth factors market.
An important factor boosting the growth potential of the market is the patent expiries of major branded drugs, such as Neupogen, Avonex, Epogen, Intron and Roferon. Expiration of major patents over the years for Erythropoietins and Colony Stimulating Factors in the US and the Europe has opened the doors for generic drugs in these regions. In Asia, Latin America, and Eastern Europe, the generic products have already been developed and marketed. As such, Erythropoietin market is very profitable due to low marketing and distribution costs. This is due to the distinct patient population and limited distribution outlets. In an untiring fight against diseases, growth factors have achieved much success over the recent years. However, safety still remains a concern due to a considerable amount of unaddressed side effects subsisting in the marketed blood growth factors. As such, development centers are busy finding new processes and formulations to enhance product characteristics and benefits of blood growth factor treatment, while minimizing side effects.
The US represents the largest regional market for growth factors worldwide, as stated by the new market research report on Growth Factors (Blood and Tissue). Europe trails behind the US, which is also the fastest growing market for growth factors. Japanese market is forecast to post a compounded annual growth rate of close to 4.3% during the analysis period. Segment-wise, Erythropoietins and Interferons are the two largest markets in the global growth factors market. The growing demand for recombinant erythropoietin for their application in chemotherapy-induced anemia is an important growth booster in the blood growth factors market.
Human recombinant technologies have triggered the growth factors market to greater heights. With the future projected to show promising growth in drug discovery and research, there is an urgent need to develop potential innovative delivery systems that would expand the acceptance of growth factors as a viable and effective therapy. In addition, the successful development of mimetic growth factors may prove to be a suitable alternative to recombinant growth factors. In years to come, the bio-market may soon witness a new era for mimetic growth factors, characterized by attributes such as higher rate of efficiency, and lower production cost associated.
Major players profiled in the report include Alseres Pharmaceuticals Inc., Amgen Inc., Bayer HealthCare Pharmaceuticals Inc., BioMimetic Therapeutics Inc., Biopharm GmbH, Bolder Biotechnology Inc., Ceregene Inc., FibroGen Inc, FzioMed Inc, Genzyme Corp., Novo Nordisk A/S, Reliance GeneMedix Plc., Johnson & Johnson, Janssen Inc., Lonza Group, Maxygen Inc., Merck Serono International S.A., NsGene A/S, PeproTech, Inc., Rentschler Biotechnologie GmbH, F. Hoffmann-La Roche Ltd., Chugai Pharmaceutical Co. Ltd., Genentech Inc., Shantha Biotechnics, Scil Proteins GmbH, Wockhardt Ltd., among others.
The research report titled “Growth Factors (Blood And Tissue): A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the Growth Factors market, current market trends, key growth drivers, recent product approvals, recent industry activity, and profiles of major/niche global as well as regional market participants. The report provides annual sales estimates and projections for Growth Factors (Blood and Tissue) market for the years 2009 through 2017 for the following geographic markets - US, Japan, Europe, and Rest of World. Key product segments analyzed include Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors. Also, a six-year (2003-2008) historic analysis is provided for an additional perspective.
For more details about this comprehensive market research report, please visit –
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/